In two new studies on lung cancer, it was shown that therapeutic intervention that either destabilizes BACH1 (Lignitto et al, 2019) or disrupts its ability to induce glycolysis (Wiel et al, 2019) have the potential to inhibit BACH1 pro-metastatic activity. Here, BACH1 is linked to lung cancer.